A detailed history of Bayesian Capital Management, LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 28,415 shares of TVTX stock, worth $488,169. This represents 0.05% of its overall portfolio holdings.

Number of Shares
28,415
Holding current value
$488,169
% of portfolio
0.05%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.89 - $15.21 $224,194 - $432,192
28,415 New
28,415 $397,000
Q1 2024

May 15, 2024

BUY
$7.18 - $9.82 $164,673 - $225,221
22,935 New
22,935 $176,000
Q2 2023

Aug 14, 2023

BUY
$15.3 - $22.61 $454,914 - $672,263
29,733 New
29,733 $456,000

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.1B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.